The COVID-19 drug associated apis market size has grown strongly in recent years. It will grow from $6.37 billion in 2023 to $6.75 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth observed in the historical period can be primarily attributed to several key factors. These include the increasing prevalence of COVID-19 infections, heightened awareness regarding treatment options available for COVID-19, expanded accessibility to drugs targeting the virus, a growing demand for COVID-19 medications used as prophylaxis, government initiatives supporting healthcare measures, and efforts to strengthen the resilience of the supply chain for these drugs. These factors collectively contributed to the growth and development of the market for COVID-19 drug-associated APIs during that period.
The COVID-19 drug associated apis market size is expected to see strongly grown in the next few years. It will grow to $8.52 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The anticipated growth in the forecast period is expected to stem from several significant factors. These include the development of novel modalities for COVID-19 drugs, a surge in clinical trials exploring potential COVID-19 treatments, a continued rise in demand for COVID-19 vaccines, the emergence of new virus variants necessitating ongoing research and drug development, vaccination campaigns aiming for widespread immunization, and a heightened focus on pandemic preparedness measures.
The surging demand for key pharmaceuticals like antiretrovirals, antimalarials, and respiratory drugs has led to increased need for active pharmaceutical ingredients (APIs) crucial in manufacturing COVID-19 medications. Remdesivir and Favipiravir are among the prominent antiviral drugs used for COVID-19 treatment. Remdesivir gained emergency approval in the USA and Japan, while the FDA approved Airsupra for bronchoconstriction and asthma prevention. The demand for bronchodilators escalated significantly due to COVID-19’s respiratory impact. Consequently, this increased demand for antivirals, antimalarials, and bronchodilators is expected to drive the market for COVID-19 drug-associated APIs.
Government initiatives focused on healthcare research and development are set to fuel growth in the COVID-19 drug-associated API market. These initiatives encompass specific programs, policies, or actions undertaken by government bodies to address healthcare needs. For instance, in 2022, the UK government allocated £260 million to bolster healthcare research and manufacture, aiming to support NHS-led health research, diagnostics, and life sciences manufacturing. Such initiatives are pivotal in fostering an environment conducive to the development, production, and distribution of COVID-19 drug-associated APIs. Major pharmaceutical players are strategizing capacity expansions to meet the escalating demand for COVID-19 drug-related APIs amid rising global COVID-19 cases. Merck & Co., Inc., in partnership with India's Heavy Water Board, aims to delve into the deuterated raw compound industry, potentially worth $1 billion in the next decade. Merck aims to support sectors like chemicals, pharmaceuticals, and electronics by supplying high-quality compounds. Avigan, currently undergoing clinical trials, is being tested for its effectiveness in treating COVID-19 patients.
Top companies in the COVID-19 drug-associated APIs market are focusing on innovation, such as oral treatments, to gain a competitive advantage. In 2023, Pfizer Inc.'s PAXLOVID, an oral SARS-CoV-2 protease inhibitor approved by the FDA, demonstrated an 89% reduction in hospitalization or death risk compared to a placebo in high-risk, non-hospitalized adults with COVID-19. Designed for early administration, it aims to prevent severe illness and hospitalization, making a significant impact in managing the infection.
In January 2023, Sterling Pharma Solutions, a US-based pharmaceutical company, completed the acquisition of an undisclosed active pharmaceutical ingredient (API) manufacturing facility from Novartis, a prominent pharmaceutical company based in the US. This strategic acquisition marks an expansion of Sterling's capabilities in API manufacturing. The deal also includes a continued supply arrangement between Sterling and Novartis, ensuring the manufacturing of several APIs utilized in cardiovascular, immunology, and oncology medications. Novartis AG, known for its production of active pharmaceutical ingredients, initiated this transfer as part of their strategic reorganization.
Major companies operating in the COVID-19 drug associated apis market include Dr. Reddy's Laboratories Ltd., Lianyungang Guike Pharmaceutical CO. LTD., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd., Zhejiang Yatai Pharmaceutical Co. Ltd., Zhejiang Guobang Pharmaceutical Co Ltd., Cipla Limited, Shandong Boyuan Pharmaceutical Co. Ltd., Aspiro Pharma Ltd., Qilu Antibiotics Pharmaceutical Co. Ltd., Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co.Inc., Hetero Labs Ltd., Geno Pharmaceuticals Ltd., Mylan Laboratories Ltd., Ipca Laboratories Limited, Zydus Takeda Healthcare Private Limited, Mangalam Drugs & Organics, Wallace Pharmaceuticals, Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., Zhejiang NHU Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Zhejiang Yongtai Technology Co. Ltd., Zhejiang Zhebei Pharmaceutical Co. Ltd., Zhejiang Tianyu Pharmaceutical Co. Ltd., Zhejiang Aisheng Pharmaceutical Co. Ltd., Zhejiang Aokang Pharmaceutical Co. Ltd., Zhejiang Anji Huifeng Surgical Dressings Co. Ltd.
North America was the largest region in the COVID-19 drug-associated APIs market in 2023. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated apis market share during the forecast period. The regions covered in the COVID-19 drug associated apis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the COVID-19 drug associated apis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary classes of drugs categorized as COVID-19 drug-associated APIs encompass antimalarials, bronchodilators, antibiotics, antivirals, and other related categories. Antimalarial drugs, specifically, are antiparasitic agents used to treat or prevent malaria, commonly sourced from organic origins. These drugs exist in various forms, including generic and branded versions, and are involved in different business models such as captive API (produced for internal use) and merchant API (commercially available for external sales).
The COVID-19 drug-associated APIs market research report is one of a series of new reports provides COVID-19 drug-associated APIs market statistics, including global market size, regional shares, competitors with a COVID-19 drug-associated APIs market share, detailed COVID-19 drug-associated APIs market segments, COVID-19 drug-associated APIs market trends and opportunities, and any further data you may need to thrive in the COVID-19 drug-associated APIs industry. This COVID-19 drug-associated APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The COVID-19 drug-associated APIs market consists of sales of acetaminophen (Tylenol) and ibuprofen (Motrin, Advil). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The COVID-19 drug associated apis market size is expected to see strongly grown in the next few years. It will grow to $8.52 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The anticipated growth in the forecast period is expected to stem from several significant factors. These include the development of novel modalities for COVID-19 drugs, a surge in clinical trials exploring potential COVID-19 treatments, a continued rise in demand for COVID-19 vaccines, the emergence of new virus variants necessitating ongoing research and drug development, vaccination campaigns aiming for widespread immunization, and a heightened focus on pandemic preparedness measures.
The surging demand for key pharmaceuticals like antiretrovirals, antimalarials, and respiratory drugs has led to increased need for active pharmaceutical ingredients (APIs) crucial in manufacturing COVID-19 medications. Remdesivir and Favipiravir are among the prominent antiviral drugs used for COVID-19 treatment. Remdesivir gained emergency approval in the USA and Japan, while the FDA approved Airsupra for bronchoconstriction and asthma prevention. The demand for bronchodilators escalated significantly due to COVID-19’s respiratory impact. Consequently, this increased demand for antivirals, antimalarials, and bronchodilators is expected to drive the market for COVID-19 drug-associated APIs.
Government initiatives focused on healthcare research and development are set to fuel growth in the COVID-19 drug-associated API market. These initiatives encompass specific programs, policies, or actions undertaken by government bodies to address healthcare needs. For instance, in 2022, the UK government allocated £260 million to bolster healthcare research and manufacture, aiming to support NHS-led health research, diagnostics, and life sciences manufacturing. Such initiatives are pivotal in fostering an environment conducive to the development, production, and distribution of COVID-19 drug-associated APIs. Major pharmaceutical players are strategizing capacity expansions to meet the escalating demand for COVID-19 drug-related APIs amid rising global COVID-19 cases. Merck & Co., Inc., in partnership with India's Heavy Water Board, aims to delve into the deuterated raw compound industry, potentially worth $1 billion in the next decade. Merck aims to support sectors like chemicals, pharmaceuticals, and electronics by supplying high-quality compounds. Avigan, currently undergoing clinical trials, is being tested for its effectiveness in treating COVID-19 patients.
Top companies in the COVID-19 drug-associated APIs market are focusing on innovation, such as oral treatments, to gain a competitive advantage. In 2023, Pfizer Inc.'s PAXLOVID, an oral SARS-CoV-2 protease inhibitor approved by the FDA, demonstrated an 89% reduction in hospitalization or death risk compared to a placebo in high-risk, non-hospitalized adults with COVID-19. Designed for early administration, it aims to prevent severe illness and hospitalization, making a significant impact in managing the infection.
In January 2023, Sterling Pharma Solutions, a US-based pharmaceutical company, completed the acquisition of an undisclosed active pharmaceutical ingredient (API) manufacturing facility from Novartis, a prominent pharmaceutical company based in the US. This strategic acquisition marks an expansion of Sterling's capabilities in API manufacturing. The deal also includes a continued supply arrangement between Sterling and Novartis, ensuring the manufacturing of several APIs utilized in cardiovascular, immunology, and oncology medications. Novartis AG, known for its production of active pharmaceutical ingredients, initiated this transfer as part of their strategic reorganization.
Major companies operating in the COVID-19 drug associated apis market include Dr. Reddy's Laboratories Ltd., Lianyungang Guike Pharmaceutical CO. LTD., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd., Zhejiang Yatai Pharmaceutical Co. Ltd., Zhejiang Guobang Pharmaceutical Co Ltd., Cipla Limited, Shandong Boyuan Pharmaceutical Co. Ltd., Aspiro Pharma Ltd., Qilu Antibiotics Pharmaceutical Co. Ltd., Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co.Inc., Hetero Labs Ltd., Geno Pharmaceuticals Ltd., Mylan Laboratories Ltd., Ipca Laboratories Limited, Zydus Takeda Healthcare Private Limited, Mangalam Drugs & Organics, Wallace Pharmaceuticals, Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., Zhejiang NHU Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Zhejiang Yongtai Technology Co. Ltd., Zhejiang Zhebei Pharmaceutical Co. Ltd., Zhejiang Tianyu Pharmaceutical Co. Ltd., Zhejiang Aisheng Pharmaceutical Co. Ltd., Zhejiang Aokang Pharmaceutical Co. Ltd., Zhejiang Anji Huifeng Surgical Dressings Co. Ltd.
North America was the largest region in the COVID-19 drug-associated APIs market in 2023. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated apis market share during the forecast period. The regions covered in the COVID-19 drug associated apis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the COVID-19 drug associated apis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary classes of drugs categorized as COVID-19 drug-associated APIs encompass antimalarials, bronchodilators, antibiotics, antivirals, and other related categories. Antimalarial drugs, specifically, are antiparasitic agents used to treat or prevent malaria, commonly sourced from organic origins. These drugs exist in various forms, including generic and branded versions, and are involved in different business models such as captive API (produced for internal use) and merchant API (commercially available for external sales).
The COVID-19 drug-associated APIs market research report is one of a series of new reports provides COVID-19 drug-associated APIs market statistics, including global market size, regional shares, competitors with a COVID-19 drug-associated APIs market share, detailed COVID-19 drug-associated APIs market segments, COVID-19 drug-associated APIs market trends and opportunities, and any further data you may need to thrive in the COVID-19 drug-associated APIs industry. This COVID-19 drug-associated APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The COVID-19 drug-associated APIs market consists of sales of acetaminophen (Tylenol) and ibuprofen (Motrin, Advil). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. COVID-19 Drug Associated APIs Market Characteristics3. COVID-19 Drug Associated APIs Market Trends and Strategies31. Global COVID-19 Drug Associated APIs Market Competitive Benchmarking32. Global COVID-19 Drug Associated APIs Market Competitive Dashboard33. Key Mergers and Acquisitions in the COVID-19 Drug Associated APIs Market
4. COVID-19 Drug Associated APIs Market - Macro Economic Scenario
5. Global COVID-19 Drug Associated APIs Market Size and Growth
6. COVID-19 Drug Associated APIs Market Segmentation
7. COVID-19 Drug Associated APIs Market Regional and Country Analysis
8. Asia-Pacific COVID-19 Drug Associated APIs Market
9. China COVID-19 Drug Associated APIs Market
10. India COVID-19 Drug Associated APIs Market
11. Japan COVID-19 Drug Associated APIs Market
12. Australia COVID-19 Drug Associated APIs Market
13. Indonesia COVID-19 Drug Associated APIs Market
14. South Korea COVID-19 Drug Associated APIs Market
15. Western Europe COVID-19 Drug Associated APIs Market
16. UK COVID-19 Drug Associated APIs Market
17. Germany COVID-19 Drug Associated APIs Market
18. France COVID-19 Drug Associated APIs Market
19. Italy COVID-19 Drug Associated APIs Market
20. Spain COVID-19 Drug Associated APIs Market
21. Eastern Europe COVID-19 Drug Associated APIs Market
22. Russia COVID-19 Drug Associated APIs Market
23. North America COVID-19 Drug Associated APIs Market
24. USA COVID-19 Drug Associated APIs Market
25. Canada COVID-19 Drug Associated APIs Market
26. South America COVID-19 Drug Associated APIs Market
27. Brazil COVID-19 Drug Associated APIs Market
28. Middle East COVID-19 Drug Associated APIs Market
29. Africa COVID-19 Drug Associated APIs Market
30. COVID-19 Drug Associated APIs Market Competitive Landscape and Company Profiles
34. COVID-19 Drug Associated APIs Market Future Outlook and Potential Analysis
35. Appendix
Executive Summary
COVID-19 Drug Associated APIs Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on covid-19 drug associated apis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for covid-19 drug associated apis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of covid 19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:
1) by Drug Class: Antimalarials; Bronchodilators; Antibiotics; Antivirals; Other Drug Class2) by Synthesis Type: Synthetic; Biotech
3) by Business Mode: Captive API; Merchant API
Key Companies Mentioned: Dr. Reddy's Laboratories Ltd.; Lianyungang Guike Pharmaceutical CO. LTD.; Alembic Pharmaceuticals Ltd.; Wockhardt Ltd.; Sandoz Srl
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Dr. Reddy's Laboratories Ltd.
- Lianyungang Guike Pharmaceutical CO. LTD.
- Alembic Pharmaceuticals Ltd.
- Wockhardt Ltd.
- Sandoz Srl
- Lupin Limited
- Aurobindo Pharma Ltd.
- Shanghai Shyndec Pharmaceutical Co. Ltd.
- Zhejiang Yatai Pharmaceutical Co. Ltd.
- Zhejiang Guobang Pharmaceutical Co Ltd.
- Cipla Limited
- Shandong Boyuan Pharmaceutical Co. Ltd.
- Aspiro Pharma Ltd.
- Qilu Antibiotics Pharmaceutical Co. Ltd.
- Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd.
- Zhejiang Cheng Yi Pharmaceutical
- Star Lake Bioscience Co.Inc.
- Hetero Labs Ltd.
- Geno Pharmaceuticals Ltd.
- Mylan Laboratories Ltd.
- Ipca Laboratories Limited
- Zydus Takeda Healthcare Private Limited
- Mangalam Drugs & Organics
- Wallace Pharmaceuticals
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Zhejiang Huahai Pharmaceutical Co. Ltd.
- Zhejiang Jiuzhou Pharmaceutical Co. Ltd.
- Zhejiang NHU Co. Ltd.
- Zhejiang Xianju Pharmaceutical Co. Ltd.
- Zhejiang Yongtai Technology Co. Ltd.
- Zhejiang Zhebei Pharmaceutical Co. Ltd.
- Zhejiang Tianyu Pharmaceutical Co. Ltd.
- Zhejiang Aisheng Pharmaceutical Co. Ltd.
- Zhejiang Aokang Pharmaceutical Co. Ltd.
- Zhejiang Anji Huifeng Surgical Dressings Co. Ltd.
